Compare AVDL & CXM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVDL | CXM |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 1996 | 2021 |
| Metric | AVDL | CXM |
|---|---|---|
| Price | $21.63 | $7.71 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 9 |
| Target Price | ★ $18.38 | $9.89 |
| AVG Volume (30 Days) | 2.1M | ★ 2.5M |
| Earning Date | 11-04-2025 | 12-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 180.38 |
| EPS | N/A | ★ 0.42 |
| Revenue | $248,517,000.00 | ★ $839,147,000.00 |
| Revenue This Year | $65.47 | $8.25 |
| Revenue Next Year | $30.88 | $3.44 |
| P/E Ratio | ★ N/A | $18.16 |
| Revenue Growth | ★ 79.88 | 6.48 |
| 52 Week Low | $6.38 | $6.75 |
| 52 Week High | $23.57 | $9.69 |
| Indicator | AVDL | CXM |
|---|---|---|
| Relative Strength Index (RSI) | 61.54 | 51.18 |
| Support Level | $21.36 | $7.61 |
| Resistance Level | $21.68 | $7.98 |
| Average True Range (ATR) | 0.12 | 0.19 |
| MACD | -0.12 | -0.02 |
| Stochastic Oscillator | 74.68 | 19.17 |
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.
Sprinklr Inc is engaged in enabling customer-facing teams, from Customer Service to Marketing, to collaborate across internal silos, communicate across digital channels, and leverage AI to deliver customer experiences at scale all on one unified AI-based platform. It focuses on empowering companies to deliver next-generation, unified engagement journeys that reimagine the customer's experience. Its products include Sprinklr Service, Sprinklr Social, Sprinklr Insights and Sprinklr Marketing. The company operates in the Americas, EMEA, and other countries. It derives maximum revenue from the Americas.